文献速递乳腺癌

TBCRC026:二期试验评估标准化摄取值与帕妥珠单抗联合曲妥珠单抗治疗乳腺癌病理完全缓解的相关性

TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer.
PubMed 文献 · J Clin Oncol · 2019-02-05

该二期试验纳入88例II/III期、雌激素受体阴性、HER2阳性乳腺癌患者,接受4周期新辅助帕妥珠单抗联合曲妥珠单抗(PT)治疗。基线及C1D15行[18F]FDG PET/CT,SULmax变化百分比预测pCR的AUC为0.76(90%CI 0.67-0.85),拒绝原假设;pCR率34%,C1D15 SULmax下降≥40%者pCR比例更高(86% vs 46%,P<.001)。

要点

  • C1D15 SULmax下降≥40%预测pCR的阴性预测值88%、阳性预测值49%。
  • C1D15 SULmax≤3预测pCR的阴性预测值94%、阳性预测值55%。
  • pCR患者C1D15 SULmax中位下降63.8%,非pCR患者下降33.5%(P<.001)。

核心结论

  • SULmax的早期变化可预测雌激素受体阴性、HER2阳性乳腺癌患者对4周期PT新辅助治疗的应答,该定量影像策略经优化后可能有助于更个体化的治疗。

研究设计与样本

  • 二期试验纳入88例II/III期、雌激素受体阴性、HER2阳性乳腺癌患者,接受4周期新辅助PT治疗。
  • 基线及PT开始后第15天(C1D15)行[18F]FDG PET/CT,评估SULmax变化百分比预测pCR。
  • 需80例可评估患者检验原假设:C1D15 SULmax变化百分比预测pCR的AUC≤0.65,单侧I类错误率10%。

主要发现

  • 88例入组,83例可评估,85%(75/88)完成全部4周期PT。
  • 单纯PT后pCR率为34%。
  • ROC分析AUC为0.76(90%CI 0.67-0.85),拒绝原假设。
  • pCR组 vs 非pCR组:C1D15 SULmax中位下降63.8% vs 33.5%(P<.001);SULmax下降≥40%比例86% vs 46%(P<.001;阴性预测值88%,阳性预测值49%);C1D15 SULmax中位值1.6 vs 3.9(P<.001);C1D15 SULmax≤3比例93% vs 38%(P<.001;阴性预测值94%,阳性预测值55%)。

临床怎么用

  • 作者认为,该定量影像策略经优化后可能有助于在雌激素受体阴性、HER2阳性乳腺癌中实现更个体化的治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Predictive biomarkers to identify patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer who may benefit from targeted therapy alone are required. We hypothesized that early measurements of tumor maximum standardized uptake values corrected for lean body mass (SULmax) on [18F]fluorodeoxyglucose positron emission tomography/computed tomography would predict pathologic complete response (pCR) to neoadjuvant pertuzumab and trastuzumab (PT). PATIENTS AND METHODS: Patients with stage II/III, estrogen receptor-negative, HER2-positive breast cancer received four cycles of neoadjuvant PT. [18F]Fluorodeoxyglucose positron emission tomography/computed tomography was performed at baseline and 15 days after PT initiation (C1D15). Eighty evaluable patients were required to test the null hypothesis that the area under the curve of percentage of change in SULmax by C1D15 predicting pCR is less than or equal to 0.65, with a one-sided type I error rate of 10%. RESULTS: Eighty-eight women were enrolled (83 evaluable), and 85% (75 of 88) completed all four cycles of PT. pCR after PT alone was 34%. Receiver operating characteristic analysis yielded an area under the curve of 0.76 (90% CI, 0.67 to 0.85), which rejected the null hypothesis. Between patients who obtained pCR versus not, a significant difference in median percent reduction in SULmax by C1D15 was observed (63.8% v 33.5%; P < .001), an SULmax reduction greater than or equal to 40% was more prevalent (86% v 46%; P < .001; negative predictive value, 88%; positive predictive value, 49%), and a significant difference in median C1D15 SULmax (1.6 v 3.9; P < .001) and higher proportion of C1D15 SULmax less than or equal to 3 (93% v 38%; P < .001; negative predictive value, 94%; positive predictive value, 55%) were observed. CONCLUSION: Early changes in SULmax predict response to four cycles of PT in estrogen receptor-negative, HER2-positive breast cancer. Once optimized, this quantitative imaging strategy may facilitate a more tailored approach to therapy in this setting.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Connolly RM, Leal JP, Solnes L, et al. TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. J Clin Oncol. 2019. PMID: 30721110. doi:10.1200/JCO.2018.78.7986

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。